| LPTX Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the LPTX shares outstanding history going back to 1/24/2017:
Also see: LPTX Market Cap History LPTX YTD Return |
LPTX Shares Outstanding History — Leap Therapeutics Share Count Over Time
As of 8/11/2025 Leap Therapeutics has 41.44 million LPTX shares outstanding. Investors often track the LPTX shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows LPTX share count trends over time, with 35 historical shares outstanding datapoints presented, dating back to 1/24/2017.
| LPTX Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LPTX Historical Shares Outstanding: +55.74% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LPTX Stock Price Chart |
| About Cypherpunk Technologies Inc |
| Leap Therapeutics, Inc. is a biopharmaceutical company. Co. is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. We show 35 historical shares outstanding datapoints in our coverage of LPTX's shares outstanding history. Understanding the changing numbers of LPTX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like LPTX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching LPTX by allowing them to research LPTX shares outstanding history as well as any other stock in our coverage universe. |
| LPTX Current Stock Quote |
Quotes delayed 20 minutes  Free LPTX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| LPTX Share Performance |
| Shares Outstanding Peers |
| Leap Therapeutics (LPTX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
LQDA Shares Outstanding History LRMR Shares Outstanding History LSTA Shares Outstanding History LTRN Shares Outstanding History LUCD Shares Outstanding History LUMO Shares Outstanding History LUNG Shares Outstanding History LVGO Shares Outstanding History LXEO Shares Outstanding History LXRX Shares Outstanding History More Healthcare companies » |
LPTX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
